Education
About Us
Working with TipRanks
Follow Us
Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$30.45M
Enterprise ValueAU$29.98M
Total Cash (Recent Filing)AU$2.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,691,591,400
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces long-term financial risk and interest burden, giving management flexibility to allocate capital to R&D or partnerships. Over a 2–6 month horizon this structural strength extends the company’s runway versus leveraged peers, easing refinancing pressure.
Narrowing Net LossesA materially smaller net loss signals improving expense control or progress in program efficiency. This trend, if sustained, improves the company’s odds of reaching operating breakeven over time and reduces near-term funding intensity required to sustain development activities.
Specialized Regenerative Medicine FocusA clear focus on cell-based regenerative therapies aligns with durable structural demand for novel chronic-disease treatments and creates high scientific and regulatory barriers to entry. This specialization can yield long-term competitive moats via IP, clinical know-how and niche market positioning.
Bears Say
Effectively No RevenueLack of meaningful recurring revenue makes the business dependent on external capital rather than operating cash generation. Over the medium term this increases dilution and financing risk, constrains reinvestment in trials and commercialization, and weakens self-sustainability.
Persistent Negative Cash FlowConsistent operating and free cash outflows indicate structural cash burn and an inability to self-fund development or scaling. This persistent deficit necessitates continued fundraising, which can dilute shareholders and distract management from long-term strategic execution.
Declining Equity And Shrinking AssetsErosion of equity and material declines in assets reduce the company’s financial buffer and operational flexibility. Over a multi-month horizon this weakens capacity to absorb trial setbacks, secure partnerships, or invest in commercialization without dilutive financing or asset sales.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$30.45M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 10 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Aug 28, 2025. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 1,691,591,400 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-30.33%
Trailing 12-Months
Asset Growth
-26.28%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―